Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study active

Novartis appears this week as a trial collaborator or sponsor across three registry updates spanning melanoma, immune thrombocytopenia, and refractive surgery.

• The Phase II "Neo Trio" trial testing neoadjuvant dabrafenib, trametinib and/or pembrolizumab in BRAF V600 mutant resectable Stage IIIB/C/D melanoma posted results this week. The study, sponsored by Melanoma Institute Australia with Merck Sharp & Dohme LLC and Novartis as collaborators, aims to determine which of three drug combinations best shrinks tumors before surgery and prevents recurrence after surgery.¹ The trial's status is active, not recruiting, with primary completion recorded as 2022-01-02 and results first posted 2026-08-24.
• Novartis Pharmaceuticals is sponsoring a new observational study on treatment preferences in primary immune thrombocytopenia (ITP), now recruiting. The study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia in the United States by conducting a preference elicitation survey.² The trial plans to enroll an estimated 100 participants² across adults treated in first-line or second-line settings.
• A Phase 4 study evaluating Alcon's WaveLight Plus LASIK platform, with Alcon (a Novartis company) as collaborator, is recruiting. The trial, led by Vance Thompson Vision, aims to provide comprehensive evaluation of WaveLight Plus technology by assessing its impact on both functional low-light vision and patient reported outcomes.³ Enrollment is estimated at 50 participants³, with primary completion expected in 2027-09.